View More Recent Stories

Nov 26, 2021 08:30AM Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Nov 25, 2021 06:00PM Numinus Announces Departure of Stacey Wallin
Nov 22, 2021 08:30AM Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
Nov 19, 2021 08:30AM Numinus to Begin Trading on the OTC Under Symbol NUMIF
Nov 10, 2021 05:00AM Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Oct 26, 2021 09:00AM Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami
Oct 20, 2021 09:00AM Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Oct 8, 2021 09:00AM Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Oct 6, 2021 09:00AM Numinus to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
Sep 23, 2021 09:00AM Numinus Completes Acquisition of Neurology Centre of Toronto
Sep 2, 2021 09:00AM Numinus to Participate in Upcoming Investor Conferences in September 2021
Jul 29, 2021 06:00PM Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology
Jul 12, 2021 08:00AM Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Jul 6, 2021 08:00AM Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology
Jun 25, 2021 06:45PM Numinus Announces Update to Escrow Release Schedule
Jun 24, 2021 07:45PM Numinus Announces Grant of Stock Options
Jun 24, 2021 08:00AM Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Jun 18, 2021 08:00AM Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
Jun 17, 2021 07:00AM Ketamine One Highlights Psychedelic Research and Announces New Clinical Trial
May 11, 2021 09:00AM Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Mar 2, 2021 09:00AM OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development
Dec 2, 2020 08:00AM Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
Oct 14, 2020 08:30AM Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
Sep 24, 2020 08:30AM Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
View More Recent Stories